These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11390004)

  • 81. Cost effectiveness of screening for cardiovascular disease with measures of coronary calcium.
    Shaw LJ; Raggi P; Berman DS; Callister TQ
    Prog Cardiovasc Dis; 2003; 46(2):171-84. PubMed ID: 14505290
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Cost-effectiveness analysis of strategies for screening prostatic cancer.
    Launois R
    Dev Health Econ Public Policy; 1992; 1():81-108. PubMed ID: 10151755
    [No Abstract]   [Full Text] [Related]  

  • 83. The Regimen of Computed Tomography Screening for Lung Cancer: Lessons Learned Over 25 Years From the International Early Lung Cancer Action Program.
    Henschke CI; Yip R; Shaham D; Zulueta JJ; Aguayo SM; Reeves AP; Jirapatnakul A; Avila R; Moghanaki D; Yankelevitz DF;
    J Thorac Imaging; 2021 Jan; 36(1):6-23. PubMed ID: 32520848
    [TBL] [Abstract][Full Text] [Related]  

  • 84. A doubly robust approach for cost-effectiveness estimation from observational data.
    Li J; Vachani A; Epstein A; Mitra N
    Stat Methods Med Res; 2018 Oct; 27(10):3126-3138. PubMed ID: 29298637
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Comment on: Jaine et al Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand. Lung Cancer 2018, 124, 233-240. 2018/10/01. DOI: 10.1016/j.lungcan.2018.08.004.
    Crengle S
    Lung Cancer; 2020 Jul; 145():219-220. PubMed ID: 32446534
    [No Abstract]   [Full Text] [Related]  

  • 86. [Benefit-risk analysis of mass screening for lung cancer].
    Iinuma T; Tateno Y
    Nihon Igaku Hoshasen Gakkai Zasshi; 1990 Feb; 50(2):101-6. PubMed ID: 2362790
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Expected Cost Savings From Low-Dose Computed Tomography Scan Screening for Lung Cancer in Alberta, Canada.
    Thanh NX; Pham TM; Waye A; Tremblay A; Yang H; Dean ML; Wasylak T; Sangha R; Stewart D
    JTO Clin Res Rep; 2022 Jul; 3(7):100350. PubMed ID: 35769390
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Is the ``$1000 Genome'' really $1000? Understanding the full benefits and costs of genomic sequencing.
    Phillips KA; Pletcher MJ; Ladabaum U
    Technol Health Care; 2015; 23(3):373-9. PubMed ID: 25669213
    [No Abstract]   [Full Text] [Related]  

  • 89. Supplementary data for a model-based health economic evaluation on lung cancer screening with low-dose computed tomography in a high-risk population.
    Du Y; Sidorenkov G; Heuvelmans MA; Groen HJM; Vermeulen KM; Greuter MJW; de Bock GH
    Data Brief; 2020 Aug; 31():105999. PubMed ID: 32676532
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Epidemiology of screening for cancer.
    Spratt JS
    Curr Probl Cancer; 1982 Feb; 6(8):1-58. PubMed ID: 6804177
    [No Abstract]   [Full Text] [Related]  

  • 91. ON THE ORIGIN OF LUNG CANCER DEVELOPMENT.
    Bolgova LS; Tuganova TN; Alekseenko OI; Ponomarenko AA
    Exp Oncol; 2022 May; 44(1):17-22. PubMed ID: 35548970
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Correction: Cost-Effectiveness of Lung Cancer Screening Using Low-Dose Computed Tomography Based on Start Age and Interval in China: Modeling Study.
    Zhao Z; Du L; Li Y; Wang L; Wang Y; Yang Y; Dong H
    JMIR Public Health Surveill; 2022 Oct; 8(10):e43025. PubMed ID: 36252229
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
    Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
    Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis.
    Mahadevia PJ; Fleisher LA; Frick KD; Eng J; Goodman SN; Powe NR
    JAMA; 2003 Jan; 289(3):313-22. PubMed ID: 12525232
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Cost-effectiveness of computed tomography screening for lung cancer in the United States.
    McMahon PM; Kong CY; Bouzan C; Weinstein MC; Cipriano LE; Tramontano AC; Johnson BE; Weeks JC; Gazelle GS
    J Thorac Oncol; 2011 Nov; 6(11):1841-8. PubMed ID: 21892105
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Economic decision analysis model of screening for lung cancer.
    Marshall D; Simpson KN; Earle CC; Chu CW
    Eur J Cancer; 2001 Sep; 37(14):1759-67. PubMed ID: 11549429
    [TBL] [Abstract][Full Text] [Related]  

  • 97. EarlyCDT Lung blood test for risk classification of solid pulmonary nodules: systematic review and economic evaluation.
    Duarte A; Corbett M; Melton H; Harden M; Palmer S; Soares M; Simmonds M
    Health Technol Assess; 2022 Dec; 26(49):1-184. PubMed ID: 36534989
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Cost-Effectiveness Analyses of Lung Cancer Screening Using Low-Dose Computed Tomography: A Systematic Review Assessing Strategy Comparison and Risk Stratification.
    Fabbro M; Hahn K; Novaes O; Ó'Grálaigh M; O'Mahony JF
    Pharmacoecon Open; 2022 Nov; 6(6):773-786. PubMed ID: 36040557
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Measuring Value: Cost-Effectiveness Analysis for Occupational Therapy.
    Morrow C; Simpson K
    Am J Occup Ther; 2022 Jan; 76(1):. PubMed ID: 35019968
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Clinical impact and cost-effectiveness of integrating smoking cessation into lung cancer screening: a microsimulation model.
    Evans WK; Gauvreau CL; Flanagan WM; Memon S; Yong JHE; Goffin JR; Fitzgerald NR; Wolfson M; Miller AB
    CMAJ Open; 2020; 8(3):E585-E592. PubMed ID: 32963023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.